Combined Modality Management of Operable Breast Cancer (Q39800715)

14 September 2017

1 reference

title

Combined modality management of operable breast cancer (English)

1 reference

14 September 2017

Combined Modality Management of Operable Breast Cancer (English)

1 reference

https://api.crossref.org/works/10.1007/978-3-642-81332-0_12

13 April 2023

author name string

A. Rossi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A379938

13 April 2023

P. Valagussa

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A379938

13 April 2023

G. Bonadonna

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A379938

13 April 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=379938

13 April 2023

publication date

1 January 1978

1 reference

full work available at URL

14 September 2017

http://link.springer.com/content/pdf/10.1007/978-3-642-81332-0_12.pdf

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1007/978-3-642-81332-0_12

Recent Results in Cancer Research

13 April 2023

published in

1 reference

14 September 2017

volume

68

1 reference

14 September 2017

page(s)

80-97

1 reference

Repeated adjuvant chemotherapy with phenylalanine mustard or 5-fluorouracil, cyclophosphamide, and prednisone with or without radiation, after mastectomy for breast cancer

14 September 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1007/978-3-642-81332-0_12

Nonlymphomatous malignant tumors complicating Hodgkin's disease. Possible association with intensive therapy

13 April 2023

2

1 reference

https://api.crossref.org/works/10.1007/978-3-642-81332-0_12

Adjuvant castration versus adjuvant chemotherapy

13 April 2023

3

1 reference

https://api.crossref.org/works/10.1007/978-3-642-81332-0_12

Combination Chemotherapy as an Adjuvant Treatment in Operable Breast Cancer

13 April 2023

4

1 reference

https://api.crossref.org/works/10.1007/978-3-642-81332-0_12

The CMF program for operable breast cancer with positive axillary nodes:Updated analysis on the disease-free interval, site of relapse and drug tolerance

13 April 2023

5

1 reference

https://api.crossref.org/works/10.1007/978-3-642-81332-0_12

Chemotherapy in Prevention of the Recurrence of Resectable Cancer

13 April 2023

7

1 reference

https://api.crossref.org/works/10.1007/978-3-642-81332-0_12

Intensive postoperative chemoimmunotherapy for patients with stage II and stage III breast cancer

13 April 2023

11

1 reference

https://api.crossref.org/works/10.1007/978-3-642-81332-0_12

Second malignancies complicating Hodgkin's disease in remission

13 April 2023

12

1 reference

https://api.crossref.org/works/10.1007/978-3-642-81332-0_12

Systemic treatment of breast cancer: past, present and future

13 April 2023

13

1 reference

https://api.crossref.org/works/10.1007/978-3-642-81332-0_12

Integration of chemotherapy into combined modality treatment of solid tumors VII. Adenocarcinoma of the breast

13 April 2023

14

1 reference

https://api.crossref.org/works/10.1007/978-3-642-81332-0_12

Breast cancer: reports of new therapy are greatly exaggerated

13 April 2023

18

1 reference

https://api.crossref.org/works/10.1007/978-3-642-81332-0_12

Adrenalectomy with radical mastectomy in the treatment of high-risk breast cancer

13 April 2023

19

1 reference

https://api.crossref.org/works/10.1007/978-3-642-81332-0_12

1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings

13 April 2023

23

1 reference

https://api.crossref.org/works/10.1007/978-3-642-81332-0_12

Comparison of radical mastectomy with alternative treatments for primary breast cancer:A first report of results from a prospective randomized clinical trial

13 April 2023

24

1 reference

https://api.crossref.org/works/10.1007/978-3-642-81332-0_12

Postoperative radiotherapy in the treatment of breast cancer: results of the NSABP clinical trial.

13 April 2023

26

1 reference

https://api.crossref.org/works/10.1007/978-3-642-81332-0_12

Acute Leukemia in Multiple Myeloma

13 April 2023

29

1 reference

https://api.crossref.org/works/10.1007/978-3-642-81332-0_12

Systemic therapy for metastatic breast cancer

13 April 2023

32

1 reference

https://api.crossref.org/works/10.1007/978-3-642-81332-0_12

Editorial: Major advance in breast-cancer therapy

13 April 2023

33

1 reference

https://api.crossref.org/works/10.1007/978-3-642-81332-0_12

Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer

13 April 2023

37

1 reference

https://api.crossref.org/works/10.1007/978-3-642-81332-0_12

Treatment of carcinoma of the breast by radiation therapy

13 April 2023

40

1 reference

https://api.crossref.org/works/10.1007/978-3-642-81332-0_12

The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer

13 April 2023

41

1 reference

https://api.crossref.org/works/10.1007/978-3-642-81332-0_12

Current status of estrogen and progesterone receptors in breast cancer

13 April 2023

44

1 reference

https://api.crossref.org/works/10.1007/978-3-642-81332-0_12

Low incidence of estrogen receptor in breast carcinomas with rapid rates of cellular replication

13 April 2023

47

1 reference

https://api.crossref.org/works/10.1007/978-3-642-81332-0_12

Prognostic significance of tumor emboli in intramammary lymphatics in patients with mammary carcinoma

13 April 2023

50

1 reference

https://api.crossref.org/works/10.1007/978-3-642-81332-0_12

Adjuvant chemotherapy of breast cancer: is it a direct cytotoxic or has it an indirect hormone effect?

13 April 2023

51

1 reference

https://api.crossref.org/works/10.1007/978-3-642-81332-0_12

Acute Leukemia after Alkylating-Agent Therapy of Ovarian Cancer

13 April 2023

53

1 reference

https://api.crossref.org/works/10.1007/978-3-642-81332-0_12

Ovarian function in patients receiving adjuvant chemotherapy for breast cancer

13 April 2023

55

1 reference

https://api.crossref.org/works/10.1007/978-3-642-81332-0_12

Rationale for adjuvant chemotherapy

13 April 2023

56

1 reference

https://api.crossref.org/works/10.1007/978-3-642-81332-0_12

Adjuvant radiotherapy trials in breast cancer

13 April 2023

61

1 reference

https://api.crossref.org/works/10.1007/978-3-642-81332-0_12

Combined chemotherapy and surgery in breast cancer: a review

13 April 2023

62

1 reference

https://api.crossref.org/works/10.1007/978-3-642-81332-0_12

Patterns of relapse and survival following radical mastectomy.Analysis of 716 consecutive patients

13 April 2023

63

1 reference

https://api.crossref.org/works/10.1007/978-3-642-81332-0_12

Conservative treatment of breast cancer. A trial in progress at the Cancer Institute of Milan

13 April 2023

64

1 reference

https://api.crossref.org/works/10.1007/978-3-642-81332-0_12

13 April 2023

Identifiers

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=379938

13 April 2023

1 reference